Soricimed Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- Soricimed Biopharma's estimated annual revenue is currently $1.2M per year.
- Soricimed Biopharma's estimated revenue per employee is $77,500
Employee Data
- Soricimed Biopharma has 15 Employees.
- Soricimed Biopharma grew their employee count by -6% last year.
Soricimed Biopharma's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder, Chief Scientific Officer | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | VP R&D | Reveal Email/Phone |
4 | VP, Business Development | Reveal Email/Phone |
5 | President | Reveal Email/Phone |
6 | Senior Scientist | Reveal Email/Phone |
7 | Financial Analyst | Reveal Email/Phone |
8 | Administrative Support | Reveal Email/Phone |
Soricimed Biopharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.7M | 37 | 12% | N/A | N/A |
#2 | $1.2M | 15 | -6% | N/A | N/A |
#3 | $3.3M | 21 | -32% | N/A | N/A |
What Is Soricimed Biopharma?
Soricimed is a privately-held, clinical stage company dedicated to developing effective and novel targeted treatments for cancer. Since the discovery of a unique protein found in the venomous saliva of the northern short-tailed shrew in 2005, the company is committed to developing effective, highly targeted delivery peptides and powerful therapeutics for several types of solid tumour cancers, making an impact on those living with often devastating conditions. General Information and Guidelines: Soricimed strives to create informative and engaging online communities that share information in meaningful ways. We welcome and encourage your participation and engagement in thoughtful and respectful discourse.
keywords:N/AN/A
Total Funding
15
Number of Employees
$1.2M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.3M | 16 | N/A | N/A |
#2 | $3.5M | 31 | 24% | N/A |
#3 | $3.6M | 31 | -3% | N/A |
#4 | $7.2M | 36 | N/A | N/A |
#5 | $4M | 36 | N/A | N/A |